About
Dr. Noa Sher is Chief Scientific Officer at Minovia Therapeutics, a clinical-stage biotech focused on mitochondrial augmentation therapy for mitochondrial disease and age-related conditions. She trained in biochemistry at the Hebrew University and completed postdoctoral work at the Whitehead Institute at MIT and the Technion. Public sources describe her as a molecular and cellular biologist and translational research leader with prior preclinical leadership experience at Pluristem.
Areas of interest
mitochondrial medicinelongevityaging biologycell therapyrare diseasesbiomarkersbioinformaticsnext-generation sequencingregenerative medicinetranslational biotech